GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...

In comparison, I expect it to be $1.05, which is above the midpoint of the above range due to stronger sales of Cabenuva, Jemperli, Ojjaara/Omjjara, and Dovato. Was Emma Walmsley, CEO of GSK ...

In December 2024, GSK reported that the Phase III FIRST-ENGOT-OV44 trial of Zejula and Jemperli met its primary endpoint of progression-free survival in treating first-line advanced ovarian cancer.

GSK said Blenrep’s side effects, which do not affect the majority of patients, were manageable and reversible, and that Jemperli was a more targeted treatment than Keytruda. Emma Walmsley ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by new patient starts across all regions. New blood cancer drug Ojjaara/Omjjara generated ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by increased patient uptake in the United States following approval for a broader patient ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by increased patient uptake in the United States following approval for a broader patient ...